TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.

An update from Trinity Biotech ( ($TRIB) ) is now available. On August 12, 2025, Trinity Biotech announced breakthrough clinical trial results for ...

The company said its CGM+ system can deliver accurate readings across a 15-day lifespan, while also employing fewer ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...

Trinity Biotech (Nasdaq:TRIB) today announced positive clinical trial results for its next-generation continuous glucose ...

Investing.com -- Trinity Biotech plc (NASDAQ: TRIB) stock rose 4.4% following the company’s announcement of positive clinical trial results for its next-generation continuous glucose monitoring (CGM) ...

Trinity Biotech (TRIB) announced clinical trial results demonstrating a major technical breakthrough and de-risking the commercial pathway for its ...

Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for ...

Sports ‘I was not gonna miss it’: Trinity Rodman’s comeback goal seals Spirit victory Published: Aug. 04, 2025, 9:56 a.m.

CMA CGM’s investment signals growing international interest in our technology,” said Hycamite chief executive Laura Rahikka. “CMA CGM’s support will fast-track the development and adoption of our ...